Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

--Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a new chief executive following a share-price slump, according to the ...

A media report stated that an activist investor is accumulating a stake in the Wegovy maker. Wegovy and Ozempic maker Novo ...

Investing.com -- Parvus Asset Management, a London-based activist hedge fund, is acquiring a stake in Danish pharmaceutical company Novo Nordisk (NYSE: NVO ), according to The Financial Times. The ...

Why Might Some People Opt to Take an Oral Version of Wegovy Instead of Injections? There are multiple reasons why someone ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ...